1. Home
  2. ROC vs MAIA Comparison

ROC vs MAIA Comparison

Compare ROC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ROC

Rank One Computing Corporation Common stock

N/A

Current Price

$5.01

Market Cap

87.8M

Sector

N/A

ML Signal

N/A

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.34

Market Cap

77.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROC
MAIA
Founded
2015
2018
Country
United States
United States
Employees
82
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.8M
77.1M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
ROC
MAIA
Price
$5.01
$1.34
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
32.2K
543.2K
Earning Date
03-31-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.41
$0.87
52 Week High
$7.80
$3.19

Technical Indicators

Market Signals
Indicator
ROC
MAIA
Relative Strength Index (RSI) 37.50 51.46
Support Level N/A $1.24
Resistance Level $6.50 $1.46
Average True Range (ATR) 0.45 0.08
MACD -0.09 0.01
Stochastic Oscillator 32.28 50.88

Price Performance

Historical Comparison
ROC
MAIA

About ROC Rank One Computing Corporation Common stock

Rank One Computing Corp is an American artificial intelligence company. It develops AI systems that analyze visual data to identify and interpret objects and activities. The company's focus is on biometric identity, digital forensics, and real-time video analytics. It uses the term 'Vision AI,' which is an operational AI built for accuracy, speed, and auditability. The company generates revenue from the sale of access to its software platforms, maintenance services, and professional services.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: